Investor Vijay Kedia’s savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opportunity during the Covid downturn when stock prices dipped. By concentrating on the company’s promising peptide sector and its CDMO capabilities, Kedia emphasized his tactic of investing in overlooked firms with solid fundamentals, which has ultimately fostered substantial wealth growth over the years.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.